Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 5/2014

01.11.2014 | Original Article

Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience

verfasst von: Inkeun Park, Yong-Hee Kim, Dok Hyun Yoon, Sook Ryun Park, Hyeong Ryul Kim, Jong Hoon Kim, Hwoon-Yong Jung, Gin Hyug Lee, Kyung-Ja Cho, Sung-Bae Kim

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The role of non-surgical treatments (NS), such as chemoradiotherapy or radiotherapy, for clinical T1N0M0 esophageal cancer (cT1N0M0 EC) has not been well delineated. The aim of this study was to evaluate and compare the feasibility and efficacy of NS and Surgical treatment (S) in cT1N0M0 EC patients.

Methods

The medical records of patients who received treatment for cT1N0M0 EC at Asan Medical Center between2003 and 2012 were retrospectively reviewed. The baseline characteristics, treatment outcomes and complications, and survival were compared.

Results

There were 264 S and 20 NS patients with respective median ages of 69.5 and 63.0. The main histologic finding was squamous cell carcinoma in both groups (97 and 100 %, respectively). The Eastern Cooperative Oncology Group performance status and Charlson comorbidity index score were poorer in the NS group. With a median follow-up of 49.0 months, 37 S patients (14 %) and 3 NS patients (15 %) exhibited recurrence. The first sites of recurrence for S and NS patients were locoregional (21 vs. 3 patients), distant (6 vs. 0), and both locoregional and distant (9 vs. 0), respectively. The median time-to-recurrence could not be calculated in either group (log-rank test P = 0.831). The estimated median overall survival was 64.4 months (95 % CI 37.2–91.6 months) in the NS group and could not be calculated in the S group (P = 0.056).

Conclusions

Non-surgical treatments can be an effective alternative to S for patients with cT1N0M0 EC unfit for radical surgery. The role of NS for early stage EC needs to be further verified with prospective randomized trials.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef
3.
Zurück zum Zitat Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS (2014) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 46:109–123PubMedCrossRefPubMedCentral Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS (2014) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 46:109–123PubMedCrossRefPubMedCentral
4.
5.
Zurück zum Zitat Shimizu M, Zaninotto G, Nagata K, Graham DY, Lauwers GY (2013) Esophageal squamous cell carcinoma with special reference to its early stage. Best Pract Res Clin Gastroenterol 27:171–186PubMedCrossRef Shimizu M, Zaninotto G, Nagata K, Graham DY, Lauwers GY (2013) Esophageal squamous cell carcinoma with special reference to its early stage. Best Pract Res Clin Gastroenterol 27:171–186PubMedCrossRef
6.
Zurück zum Zitat Tachibana M, Yoshimura H, Kinugasa S, Hashimoto N, Dhar DK, Abe S, Monden N, Nagasue N (1997) Clinicopathological features of superficial squamous cell carcinoma of the esophagus. Am J Surg 174:49–53PubMedCrossRef Tachibana M, Yoshimura H, Kinugasa S, Hashimoto N, Dhar DK, Abe S, Monden N, Nagasue N (1997) Clinicopathological features of superficial squamous cell carcinoma of the esophagus. Am J Surg 174:49–53PubMedCrossRef
7.
Zurück zum Zitat Igaki H, Kato H, Tachimori Y, Daiko H, Fukaya M, Yajima S, Nakanishi Y (2001) Clinicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinomas of the thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg 20:1089–1094PubMedCrossRef Igaki H, Kato H, Tachimori Y, Daiko H, Fukaya M, Yajima S, Nakanishi Y (2001) Clinicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinomas of the thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg 20:1089–1094PubMedCrossRef
8.
Zurück zum Zitat Markar SR, Karthikesalingam A, Thrumurthy S, Low DE (2012) Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011. J Gastrointest Surg 16:1055–1063PubMedCrossRef Markar SR, Karthikesalingam A, Thrumurthy S, Low DE (2012) Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011. J Gastrointest Surg 16:1055–1063PubMedCrossRef
9.
Zurück zum Zitat Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979–1984PubMedCrossRef Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979–1984PubMedCrossRef
10.
Zurück zum Zitat Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598PubMedCrossRef Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598PubMedCrossRef
11.
Zurück zum Zitat Ishikawa H, Sakurai H, Yamakawa M, Saito Y, Nakayama Y, Kitamoto Y, Okamoto M, Harada K, Hasegawa M, Nakano T (2005) Clinical outcomes and prognostic factors for patients with early esophageal squamous cell carcinoma treated with definitive radiation therapy alone. J Clin Gastroenterol 39:495–500PubMedCrossRef Ishikawa H, Sakurai H, Yamakawa M, Saito Y, Nakayama Y, Kitamoto Y, Okamoto M, Harada K, Hasegawa M, Nakano T (2005) Clinical outcomes and prognostic factors for patients with early esophageal squamous cell carcinoma treated with definitive radiation therapy alone. J Clin Gastroenterol 39:495–500PubMedCrossRef
12.
Zurück zum Zitat Motoori M, Yano M, Ishihara R, Yamamoto S, Kawaguchi Y, Tanaka K, Kishi K, Miyashiro I, Fujiwara Y, Shingai T, Noura S, Ohue M, Ohigashi H, Nakamura S, Ishikawa O (2012) Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol 19:2135–2141PubMedCrossRef Motoori M, Yano M, Ishihara R, Yamamoto S, Kawaguchi Y, Tanaka K, Kishi K, Miyashiro I, Fujiwara Y, Shingai T, Noura S, Ohue M, Ohigashi H, Nakamura S, Ishikawa O (2012) Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol 19:2135–2141PubMedCrossRef
13.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef
14.
15.
Zurück zum Zitat Blencowe NS, Strong S, McNair AG, Brookes ST, Crosby T, Griffin SM, Blazeby JM (2012) Reporting of short-term clinical outcomes after esophagectomy: a systematic review. Ann Surg 255:658–666PubMedCrossRef Blencowe NS, Strong S, McNair AG, Brookes ST, Crosby T, Griffin SM, Blazeby JM (2012) Reporting of short-term clinical outcomes after esophagectomy: a systematic review. Ann Surg 255:658–666PubMedCrossRef
16.
Zurück zum Zitat Yoo C, Park JH, Yoon DH, Park SI, Kim HR, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Kim YH, Kim SB (2012) Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. Ann Thorac Surg 94:1862–1868PubMedCrossRef Yoo C, Park JH, Yoon DH, Park SI, Kim HR, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Kim YH, Kim SB (2012) Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. Ann Thorac Surg 94:1862–1868PubMedCrossRef
17.
Zurück zum Zitat Rosch T (1995) Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am 5:537–547PubMed Rosch T (1995) Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am 5:537–547PubMed
18.
Zurück zum Zitat Chandawarkar RY, Kakegawa T, Fujita H, Yamana H, Toh Y, Fujitoh H (1996) Endosonography for preoperative staging of specific nodal groups associated with esophageal cancer. World J Surg 20:700–702PubMedCrossRef Chandawarkar RY, Kakegawa T, Fujita H, Yamana H, Toh Y, Fujitoh H (1996) Endosonography for preoperative staging of specific nodal groups associated with esophageal cancer. World J Surg 20:700–702PubMedCrossRef
19.
Zurück zum Zitat Young PE, Gentry AB, Acosta RD, Greenwald BD, Riddle M (2010) Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus. Clin Gastroenterol Hepatol 8:1037–1041PubMedCrossRef Young PE, Gentry AB, Acosta RD, Greenwald BD, Riddle M (2010) Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus. Clin Gastroenterol Hepatol 8:1037–1041PubMedCrossRef
20.
Zurück zum Zitat van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD (2008) Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98:547–557PubMedCrossRefPubMedCentral van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD (2008) Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98:547–557PubMedCrossRefPubMedCentral
21.
Zurück zum Zitat Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A, Federation Francophone de Cancerologie D, Group U-G (2014) Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 15:305–314PubMedCrossRef Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A, Federation Francophone de Cancerologie D, Group U-G (2014) Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 15:305–314PubMedCrossRef
22.
Zurück zum Zitat Decker G, Coosemans W, De Leyn P, Decaluwe H, Nafteux P, Van Raemdonck D, Lerut T (2009) Minimally invasive esophagectomy for cancer. Eur J Cardiothorac Surg 35:13–20 (discussion 20–21)PubMedCrossRef Decker G, Coosemans W, De Leyn P, Decaluwe H, Nafteux P, Van Raemdonck D, Lerut T (2009) Minimally invasive esophagectomy for cancer. Eur J Cardiothorac Surg 35:13–20 (discussion 20–21)PubMedCrossRef
Metadaten
Titel
Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience
verfasst von
Inkeun Park
Yong-Hee Kim
Dok Hyun Yoon
Sook Ryun Park
Hyeong Ryul Kim
Jong Hoon Kim
Hwoon-Yong Jung
Gin Hyug Lee
Kyung-Ja Cho
Sung-Bae Kim
Publikationsdatum
01.11.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 5/2014
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-014-2573-y

Weitere Artikel der Ausgabe 5/2014

Cancer Chemotherapy and Pharmacology 5/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.